VALGAN is a prodrug of ganciclovir with improved oral bioavailability. Once ingested, it converts into ganciclovir in the body, inhibiting viral DNA synthesis and controlling cytomegalovirus replication.
Recommended for:
Organ transplant recipients for CMV prophylaxis
HIV-positive individuals with active CMV disease
Patients with compromised immune systems at risk of CMV
Severe CMV infections under medical supervision
Treatment of active CMV retinitis in AIDS patients
Prevention of CMV disease in kidney, heart, and other organ transplant recipients
VALGAN is taken orally once or twice daily, depending on the patient’s weight, renal function, and treatment plan, and always under medical supervision.
Contraindications:
Hypersensitivity to ganciclovir or valganciclovir
Severe renal impairment
Use during pregnancy or breastfeeding without medical advice
Side Effects:
Neutropenia and thrombocytopenia
Nausea, vomiting, diarrhoea
Renal function disturbances
Fatigue
Headache, seizures
